- |||||||||| Mytesi (crofelemer) / Jaguar Health
Journal: Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles. (Pubmed Central) - Nov 27, 2019
The TuTuGenetics software, which moves a sliding window of 8 to 10 amino acids through the amino acid alignment, was combined with the Immune Epitope Data Base (IEDB) to automatically calculate the theoretical binding affinity of identified epitopes to the HLA alleles for each individual. We identified 15 conserved epitopes in Pol (11), Gag (3), and Nef (1) according to their potential presentation by the dominant HLA-A and B alleles and now propose to use the corresponding conserved peptides in a multi-epitopic vaccine (HLA-fitted VAC, HFVAC).
- |||||||||| Mytesi (crofelemer) / Jaguar Health, Knight Therap
Journal: Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer. (Pubmed Central) - Jul 17, 2019
Three of the newly identified GALNT12 missense variants (p.His101Gln, p.Ile142Thr, p.Val290Phe) demonstrated a marked loss (> 2-fold reduction) of enzymatic activity compared to wild-type (P?0.05), while p.Glu239Gln exhibited a ?2-fold reduction in activity (P = 0.077). These findings provide strong, independent evidence for the association of GALNT12 defects with CRC-susceptibility; underscoring implications for glycosylation pathway defects in CRC.
- |||||||||| Fulyzaq (crofelemer) / Napo Pharma, Bausch Health
Journal: Atypical coronary artery aneurysms due to Kawasaki disease in Noonan syndrome with a novel PTPN11 mutation. (Pubmed Central) - May 29, 2019
We report a 3-year-old boy with giant and atypical coronary artery aneurysms in the acute phase of Kawasaki disease, despite appropriate therapeutic intervention, in Noonan syndrome with a novel heterozygous PTPN11 mutation, c. 907 G>A (p.Asp303Asn). We hypothesised that this PTPN11 mutation might affect both hyperinflammation caused by Kawasaki disease and vascular fragility in the coronary artery, resulting in coronary artery aneurysms.
- |||||||||| Mytesi (crofelemer) / Jaguar Health, Knight Therap, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: HALT-D: Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients (clinicaltrials.gov) - Jun 12, 2018
P2, N=52, Recruiting,
We hypothesised that this PTPN11 mutation might affect both hyperinflammation caused by Kawasaki disease and vascular fragility in the coronary artery, resulting in coronary artery aneurysms. Trial completion date: May 2019 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- |||||||||| Mytesi (crofelemer) / Jaguar Health, Knight Therap, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date: HALT-D: Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients (clinicaltrials.gov) - Feb 2, 2017
P2, N=46, Recruiting,
HALT-D will provide important information about the feasibility and tolerability of crofelemer in preventing diarrhea for patients receiving THP or TCHP. Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Jan 2017
|
